169 related articles for article (PubMed ID: 37894421)
1. Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against
Raina K; Kandhari K; Kant R; Prasad RR; Mishra N; Maurya AK; Fox JT; Sei S; Shoemaker RH; Bosland MC; Maroni P; Agarwal C; Agarwal R
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894421
[TBL] [Abstract][Full Text] [Related]
2. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
Raina K; Kant R; Prasad RR; Kandhari K; Tomar M; Mishra N; Kumar R; Fox JT; Sei S; Shoemaker RH; Chen Y; Maroni P; Agarwal C; Agarwal R
Mol Carcinog; 2022 Jul; 61(7):717-734. PubMed ID: 35452553
[TBL] [Abstract][Full Text] [Related]
3. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.
Wright JL; Chéry L; Holt S; Lin DW; Luedeke M; Rinckleb AE; Maier C; Stanford JL
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):53-6. PubMed ID: 26503111
[TBL] [Abstract][Full Text] [Related]
4. Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer.
Fallahabadi ZR; Noori Daloii MR; Mahdian R; Behjati F; Shokrgozar MA; Abolhasani M; Asgari M; Shahrokh H
Gene; 2016 Jan; 575(2 Pt 3):755-60. PubMed ID: 26424596
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Study of Aspirin Use and Prostate Cancer Risk by
Stopsack KH; Gonzalez-Feliciano AG; Peisch SF; Downer MK; Gage RA; Finn S; Lis RT; Graff RE; Pettersson A; Pernar CH; Loda M; Kantoff PW; Ahearn TU; Mucci LA;
Cancer Epidemiol Biomarkers Prev; 2018 Oct; 27(10):1231-1233. PubMed ID: 30108097
[No Abstract] [Full Text] [Related]
6. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
7. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
8. Status of
Bhanushali A; Rao P; Raman V; Kokate P; Ambekar A; Mandva S; Bhatia S; Das BR
Prostate Int; 2018 Dec; 6(4):145-150. PubMed ID: 30505817
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between TMPRSS2: ERG and the pathological grade of prostate cancer].
Yi FX; Li H; Wei Q; Li X; Zeng H
Zhonghua Nan Ke Xue; 2015 Oct; 21(10):887-91. PubMed ID: 26665675
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
[TBL] [Abstract][Full Text] [Related]
12. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
[TBL] [Abstract][Full Text] [Related]
14. DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1.
Hong Z; Zhang W; Ding D; Huang Z; Yan Y; Cao W; Pan Y; Hou X; Weroha SJ; Karnes RJ; Wang D; Wu Q; Wu D; Huang H
Mol Cell; 2020 Sep; 79(6):1008-1023.e4. PubMed ID: 32871104
[TBL] [Abstract][Full Text] [Related]
15. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
16. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
17. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
[TBL] [Abstract][Full Text] [Related]
19. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.
Deplus R; Delliaux C; Marchand N; Flourens A; Vanpouille N; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncotarget; 2017 Feb; 8(7):11827-11840. PubMed ID: 28055969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
